[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360752-105":59,"doc-detail-360752-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","metabolomics-in-breast-cancer-insights-into-treatment-responses-disease-progression-and-prognostic-assessment","Metabolomics in breast cancer - Insights into treatment responses, disease progression, and prognostic assessment","","Alterations in metabolic pathways are a hallmark of cancer and shape breast cancer development, progression, and the distinct clinical outcomes seen across patients. Metabolic heterogeneity drives differences in therapeutic response and prognosis, making metabolomic profiling a practical route to uncover biomarkers of tumor biology and treatment-related changes. The review synthesizes metabolomic profiles to support monitoring of treatment response, adverse effects, disease progression, and prediction of patient prognosis.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/metabolomics-in-breast-cancer-insights-into-treatment-responses-disease-progression-and-prognostic-assessment/360752/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/metabolomics-in-breast-cancer-insights-into-treatment-responses-disease-progression-and-prognostic-assessment/360752.png","ImageObject",300,407,{"name":92,"@type":93},"Mary Man","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are metabolic pathway alterations important in breast cancer?","Question",{"text":112,"@type":113},"Metabolic pathway alterations are a hallmark of cancer and influence breast cancer development and progression. They also contribute to differences in therapeutic response and patient prognosis due to metabolic heterogeneity.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What does the review aim to summarize?",{"text":117,"@type":113},"The review summarizes metabolomic profiles of breast cancer patients using different biological materials and analytical methods. It focuses on their potential value as biomarkers for treatment monitoring, adverse effects, disease progression, and prognosis prediction.",{"name":119,"@type":110,"acceptedAnswer":120},"Which analytical method and biological matrices are commonly used in clinical metabolomics studies?",{"text":121,"@type":113},"Liquid chromatography-mass spectrometry is the most commonly used analytical method. Biological matrices such as serum, plasma, and tumor tissue are commonly applied in both untargeted and targeted metabolomics approaches.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360752,1790925756,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7421720224475,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Metabolomics (2026) 22:115  \n[https://doi.org/10.1007/s1](https://doi.org/10.1007/s1) 1306-026-02459-9  \nREVIEW ARTICLE  \nMetabolomics in breast cancer: insights into treatment responses, disease progression, and prognostic assessment  \nDyah L. Dewi1 · Elya Manik2 · Ema Damayanti3 · Muslih Anwar3 · Suratno3 · Syam Budi Iryanto4  \nReceived: 24 November 2025 / Accepted: 29 April 2026 / Published online: 3 July 2026 © The Author(s) 2026  \nAbstract  \nBackground Alterations in metabolic pathways are a hallmark of cancer and play a pivotal role in breast cancer development and progression. The inherent metabolic heterogeneity of breast cancer contributes to differences in therapeutic response and patients’ prognosis. Clinical metabolomics has emerged as a promising approach for identifying metabolic biomarkers that reflect tumor biology, treatment-related changes after diagnosis, and patients’ outcomes.  \nAims of review This review summarizes the metabolomic profiles of breast cancer patients, using various biological materials and analytical methods, to assess their potential role as biomarkers for monitoring therapeutic response, adverse treatment effects, tracking disease progression, and predicting prognosis.  \nKey scientific concept of review Metabolomic shifts generate unique signatures with promising potential as biomarkers for evaluating treatment response, monitoring therapeutic adverse effects, disease progression, and predicting clinical outcomes in breast cancer patients. Biological matrices, such as serum, plasma, and tumor tissue, were commonly used in both untargeted and targeted metabolomics approaches. Liquid chromatography-mass spectrometry is the most commonly used analytical method in clinical metabolomics studies. Altered metabolites were identified and linked to metabolic pathways, particularly amino acids, glucose, and fatty acids metabolism. When integrated with genomic and transcriptomic data, these metabolic fingerprints offer a multidimensional perspective on disease trajectory, thereby enhancing patient stratification and informing personalized therapeutic strategies.  \nKeywords Breast cancer · Metabolomics · Disease progression · Prognosis · Therapy responses  \n1 Introduction  \nBreast cancer remains a major health problem, owing to its high incidence and mortality rates among women worldwide (Sung et al., 2021) . While early-stage breast cancer  \nis often successfully managed through a combination of surgery, chemotherapy, radiotherapy, endocrine therapy, and targeted treatments, a substantial proportion of patients will eventually develop disease recurrence and progression, despite advances in therapeutic strategies (Early Breast  \n􀀍 Dyah L. Dewi  \n[dyah.laksmi.d@ugm.ac.id](dyah.laksmi.d@ugm.ac.id)[ ](dyah.laksmi.d@ugm.ac.id)Elya Manik[elyamanik@mail.ugm.ac.id](elyamanik@mail.ugm.ac.id)[ ](elyamanik@mail.ugm.ac.id)Ema Damayanti [emad001@brin.go.id](emad001@brin.go.id)  \nMuslih Anwar [muslih.anwar@brin.go.id](muslih.anwar@brin.go.id)[ ](muslih.anwar@brin.go.id)Suratno [nanosan80@gmail.com](nanosan80@gmail.com)  \nSyam Budi Iryanto  \n[syam.budi.iryanto@brin.go.id](syam.budi.iryanto@brin.go.id)  \n1 Division of Surgical Oncology, Department of Surgery, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia  \n2 Master’s Program in Biomedical Sciences, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia  \n3 Research Center for Food Technology and Processing, National Research and Innovation Agency, Gunungkidul, Yogyakarta, Indonesia  \n4 Research Center for Computing, Research Organization for Life Sciences and Environment, National Research and Innovation Agency Republic of Indonesia, Bogor, Indonesia  \nCancer Trialists’ Collaborative Group, 2005) . One of the major contributors to these clinical challenges is molecular heterogeneity of breast cancer, which comprises several distinct subtypes, including luminal A, luminal B, hu","cbCaisbXzq1KA07z","https://ap.wps.com/l/cbCaisbXzq1KA07z","pdf",1298267,32,"English","# Abstract\n## Background\n## Aims of review\n## Key scientific concept of review\n# Keywords\n# 1 Introduction","[{\"question\":\"Why are metabolic pathway alterations important in breast cancer?\",\"answer\":\"Metabolic pathway alterations are a hallmark of cancer and influence breast cancer development and progression. They also contribute to differences in therapeutic response and patient prognosis due to metabolic heterogeneity.\"},{\"question\":\"What does the review aim to summarize?\",\"answer\":\"The review summarizes metabolomic profiles of breast cancer patients using different biological materials and analytical methods. It focuses on their potential value as biomarkers for treatment monitoring, adverse effects, disease progression, and prognosis prediction.\"},{\"question\":\"Which analytical method and biological matrices are commonly used in clinical metabolomics studies?\",\"answer\":\"Liquid chromatography-mass spectrometry is the most commonly used analytical method. Biological matrices such as serum, plasma, and tumor tissue are commonly applied in both untargeted and targeted metabolomics approaches.\"}]","Metabolomics in breast cancer - Insights into treatment responses, disease progression, and prognostic assessment | PDF",1790141421,81,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3e94b5492361c2e8cf29e1ea6c1064ce.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2561bcde7a60bcaf000c91b6db0631cc.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a0541ab2bdf0cedc7acf06e09831041d.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ee884c59ce57014d733842e3d3667c44.webp",980,1301]